{"transactions":[{"id":3277230,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":151755,"kind":"person","name":"ISACSON CHRISTINA K.","position":1,"cik":"0001741281","reported_name":"ISACSON CHRISTINA K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-12T17:12:33.000Z","date":"2020-02-10","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020."}],"balance_after":50000,"derivative":{"exercise_price":12.28,"expiration_date":"2030-02-09","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-20-004313","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741281/000089924320004313/doc4.xml","form_type":"4"}},{"id":3331390,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":151755,"kind":"person","name":"ISACSON CHRISTINA K.","position":1,"cik":"0001741281","reported_name":"ISACSON CHRISTINA K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2019-12-26T16:12:03.000Z","date":"2019-12-24","kind":"sale","acquired":false,"shares":4463,"price":16.01,"value":71452.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This trade is pursuant to an active 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $16.00 to $16.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":83786,"source":{"system":"sec-edgar","filing":"0001562180-19-006266","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741281/000156218019006266/primarydocument.xml","form_type":"4"}},{"id":3331385,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":151755,"kind":"person","name":"ISACSON CHRISTINA K.","position":1,"cik":"0001741281","reported_name":"ISACSON CHRISTINA K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2019-12-26T10:12:56.000Z","date":"2019-12-23","kind":"sale","acquired":false,"shares":9867,"price":16.03,"value":158168.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This trade is pursuant to an active 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $16.00 to $16.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":88249,"source":{"system":"sec-edgar","filing":"0001562180-19-006260","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741281/000156218019006260/primarydocument.xml","form_type":"4"}},{"id":3480199,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":151755,"kind":"person","name":"ISACSON CHRISTINA K.","position":1,"cik":"0001741281","reported_name":"ISACSON CHRISTINA K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2019-06-24T16:02:36.000Z","date":"2019-06-21","kind":"sale","acquired":false,"shares":5415,"price":16.07,"value":87019.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This trade is pursuant to an active 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $16.00 to $16.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":98116,"source":{"system":"sec-edgar","filing":"0001562180-19-003624","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741281/000156218019003624/primarydocument.xml","form_type":"4"}},{"id":3670522,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":151755,"kind":"person","name":"ISACSON CHRISTINA K.","position":1,"cik":"0001741281","reported_name":"ISACSON CHRISTINA K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-07T16:16:27.000Z","date":"2019-02-05","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 12 equal quarterly installments beginning on January 1, 2019."}],"balance_after":80000,"derivative":{"exercise_price":7.13,"expiration_date":"2029-02-04","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-19-002865","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741281/000089924319002865/doc4.xml","form_type":"4"}},{"id":3882403,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":151755,"kind":"person","name":"ISACSON CHRISTINA K.","position":1,"cik":"0001741281","reported_name":"ISACSON CHRISTINA K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Series B Preferred Stock","published_at":"2018-06-27T16:30:18.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":857,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":331},"source":{"system":"sec-edgar","filing":"0000899243-18-018331","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1741281/000089924318018331/doc4.xml","form_type":"4"}},{"id":3882402,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":151755,"kind":"person","name":"ISACSON CHRISTINA K.","position":1,"cik":"0001741281","reported_name":"ISACSON CHRISTINA K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Series A Preferred Stock","published_at":"2018-06-27T16:30:18.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":6670,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2581},"source":{"system":"sec-edgar","filing":"0000899243-18-018331","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1741281/000089924318018331/doc4.xml","form_type":"4"}},{"id":3882401,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":151755,"kind":"person","name":"ISACSON CHRISTINA K.","position":1,"cik":"0001741281","reported_name":"ISACSON CHRISTINA K.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2018-06-27T16:30:18.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":2912,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."}],"balance_after":103531,"source":{"system":"sec-edgar","filing":"0000899243-18-018331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741281/000089924318018331/doc4.xml","form_type":"4"}}]}